Literature DB >> 18690796

ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout.

R Michael Tuttle1, Yvonne Lukes, Lynn Onstad, Eugeni Lushnikov, Alexander Abrosimov, Vladislav Troshin, Anatoli Tsyb, Scott Davis, Kenneth J Kopecky, Gary Francis.   

Abstract

BACKGROUND: Ionizing radiation is the strongest risk factor known for the development of thyroid neoplasia. While previous studies have demonstrated a high prevalence of ret/papillary thyroid cancer (PTC) activation in cohorts of patients developing thyroid nodules after childhood exposure to ionizing radiation, no study has directly compared ret/PTC activation with individual estimates of radiation dose to the thyroid. This study combines individual thyroid dosimetry data with molecular analysis of surgically removed thyroid nodules in order to determine if ret/PTC activation in thyroid nodules is associated with increasing estimated radiation dose from Chernobyl.
METHODS: This pilot study included adults and children diagnosed with PTC (n = 76) and children diagnosed with follicular adenomas (n = 24) during May 1986 through December 1999, who were living in the Bryansk Oblast of the Russian Federation at the time of the Chernobyl accident, who had paraffin-embedded thyroid surgical samples available and for whom an individual dose to the thyroid could be estimated. The frequency of ret/PTC activation was determined using RT-PCR analysis. Individual radiation doses to the thyroid were estimated using a semiempirical model, and data were collected by detailed interview, primarily of the participant's mother.
RESULTS: ret/PTC oncogene activation was detected in 23.8% (5/21) and 14.5% (8/55) of the childhood and adult PTC cases, respectively, and 8.3% (2/24) of the follicular adenoma cases. No statistically significant differences were noted in age at the time of exposure or diagnosis, gender, latency period, or estimated radiation dose between PTC patients with or without ret/PTC activation. Further, no significant dose-response relationship was detected among PTC patients with ret/PTC activation.
CONCLUSIONS: Factors other than individual thyroid radiation doses may influence the development and subsequent detection of ret/PTC oncogene activation in radiation related PTC arising in the Bryansk Oblast of the Russian Federation in the aftermath of the Chernobyl accident.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690796      PMCID: PMC2857448          DOI: 10.1089/thy.2008.0072

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  33 in total

1.  Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas.

Authors:  Marina N Nikiforova; Christy M Caudill; Paul Biddinger; Yuri E Nikiforov
Journal:  Int J Surg Pathol       Date:  2002-01       Impact factor: 1.271

2.  RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.

Authors:  R Elisei; C Romei; T Vorontsova; B Cosci; V Veremeychik; E Kuchinskaya; F Basolo; E P Demidchik; P Miccoli; A Pinchera; F Pacini
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

3.  Childhood thyroid cancer, radiation dose from Chernobyl, and dose uncertainties in Bryansk Oblast, Russia: a population-based case-control study.

Authors:  Kenneth J Kopecky; Valery Stepanenko; Nikolai Rivkind; Paul Voillequé; Lynn Onstad; Vladimir Shakhtarin; Evgeni Parshkov; Sergei Kulikov; Evgeni Lushnikov; Alexander Abrosimov; Vladislav Troshin; Galina Romanova; Vladimir Doroschenko; Anatoli Proshin; Anatoly Tsyb; Scott Davis
Journal:  Radiat Res       Date:  2006-08       Impact factor: 2.841

4.  RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH.

Authors:  R Cinti; L Yin; K Ilc; N Berger; F Basolo; S Cuccato; R Giannini; G Torre; P Miccoli; P Amati; G Romeo; R Corvi
Journal:  Cytogenet Cell Genet       Date:  2000

5.  Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications.

Authors:  H M Rabes; E P Demidchik; J D Sidorow; E Lengfelder; C Beimfohr; D Hoelzel; S Klugbauer
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

Review 6.  The Chernobyl accident and its consequences: update at the millennium.

Authors:  R M Tuttle; D V Becker
Journal:  Semin Nucl Med       Date:  2000-04       Impact factor: 4.446

7.  High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant.

Authors:  G A Thomas; H Bunnell; H A Cook; E D Williams; A Nerovnya; E D Cherstvoy; N D Tronko; T I Bogdanova; G Chiappetta; G Viglietto; F Pentimalli; G Salvatore; A Fusco; M Santoro; G Vecchio
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

8.  The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults.

Authors:  C L Fenton; Y Lukes; D Nicholson; C A Dinauer; G L Francis; R M Tuttle
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

Review 9.  RET oncogene activation in papillary thyroid carcinoma.

Authors:  G Tallini; S L Asa
Journal:  Adv Anat Pathol       Date:  2001-11       Impact factor: 3.875

10.  RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions.

Authors:  B J Collins; G Chiappetta; A B Schneider; M Santoro; F Pentimalli; L Fogelfeld; T Gierlowski; E Shore-Freedman; G Jaffe; A Fusco
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

View more
  13 in total

Review 1.  Exposing the thyroid to radiation: a review of its current extent, risks, and implications.

Authors:  Bridget Sinnott; Elaine Ron; Arthur B Schneider
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

2.  Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Authors:  David S Hong; Maria E Cabanillas; Jennifer Wheler; Aung Naing; Apostolia M Tsimberidou; Lei Ye; Naifa L Busaidy; Steven G Waguespack; Mike Hernandez; Adel K El Naggar; Alder K El Naggar; Savita Bidyasar; John Wright; Steven I Sherman; Razelle Kurzrock
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

3.  RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.

Authors:  Rebecca J Leeman-Neill; Alina V Brenner; Mark P Little; Tetiana I Bogdanova; Maureen Hatch; Liudmyla Y Zurnadzy; Kiyohiko Mabuchi; Mykola D Tronko; Yuri E Nikiforov
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

4.  The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.

Authors:  Susi Barollo; Loris Bertazza; Enke Baldini; Salvatore Ulisse; Elisabetta Cavedon; Marco Boscaro; Raffaele Pezzani; Caterina Mian
Journal:  Invest New Drugs       Date:  2014-05-13       Impact factor: 3.850

Review 5.  Non-malignant thyroid diseases after a wide range of radiation exposures.

Authors:  Elaine Ron; Alina Brenner
Journal:  Radiat Res       Date:  2010-09-07       Impact factor: 2.841

6.  Gain of chromosome band 7q11 in papillary thyroid carcinomas of young patients is associated with exposure to low-dose irradiation.

Authors:  Julia Hess; Gerry Thomas; Herbert Braselmann; Verena Bauer; Tatjana Bogdanova; Johannes Wienberg; Horst Zitzelsberger; Kristian Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

7.  Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study.

Authors:  Aarti Mathur; Willeford Moses; Reza Rahbari; Elham Khanafshar; Quan-Yang Duh; Orlo Clark; Electron Kebebew
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

Review 8.  Thyroid cancer gender disparity.

Authors:  Reza Rahbari; Lisa Zhang; Electron Kebebew
Journal:  Future Oncol       Date:  2010-11       Impact factor: 3.404

9.  CLIP2 as radiation biomarker in papillary thyroid carcinoma.

Authors:  M Selmansberger; A Feuchtinger; L Zurnadzhy; A Michna; J C Kaiser; M Abend; A Brenner; T Bogdanova; A Walch; K Unger; H Zitzelsberger; J Hess
Journal:  Oncogene       Date:  2014-10-06       Impact factor: 9.867

10.  Discriminating gene expression signature of radiation-induced thyroid tumors after either external exposure or internal contamination.

Authors:  Catherine Ory; Nicolas Ugolin; Martin Schlumberger; Paul Hofman; Sylvie Chevillard
Journal:  Genes (Basel)       Date:  2011-12-21       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.